Paul Maier V - 12 Jan 2026 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Reporting relationship: Director
Issuer ticker: ETON
Reported as of: 12 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jan 2026, 18:06:42 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ James R. Gruber

Key filing fact

Paul Maier V filed Form 4 for Eton Pharmaceuticals, Inc. (ETON) on 14 Jan 2026.

Key facts

This page summarizes Paul Maier V's Form 4 filing for Eton Pharmaceuticals, Inc. (ETON).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Jan 2026, 18:06.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001182615 Primary reporting owner

MAIER PAUL V

Relationship: Director
Address: C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK
Signature: /s/ James R. Gruber
Signature date: 14 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETON transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,196
Change %: +4.4%
Price: $0.000000
Shares after: 286,496
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,196
Exercise price: $15.47
Footnotes: F1

ETON transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +7,757
Change %: +2.7%
Price: $0.000000
Shares after: 294,253
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,757
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 12, 2027.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.

Footnote F3

The restricted stock units vest in one annual installment beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

SEC remarks

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.